Mercado mundial de pruebas desarrolladas en laboratorio (LDT): tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de pruebas desarrolladas en laboratorio (LDT).

Las pruebas de diagnóstico por LDT se utilizan a menudo cuando existe la necesidad de una prueba que no está disponible comercialmente o cuando las pruebas existentes no cumplen con los requisitos específicos de una población de pacientes en particular. Los laboratorios que desarrollan pruebas de diagnóstico por LDT son responsables de garantizar la precisión, la confiabilidad y la validez clínica de las pruebas, y de cumplir con los requisitos reglamentarios y los estándares de calidad. Las pruebas de diagnóstico por LDT han desempeñado un papel crucial en el avance de la medicina personalizada y los diagnósticos de precisión, ya que permiten a los laboratorios adaptar las pruebas a las necesidades específicas de cada paciente.

Data Bridge Market Research analiza que el mercado global de pruebas desarrolladas en laboratorio (LDT), que fue de USD 12,13 mil millones en 2023, se espera que alcance los USD 27,36 mil millones para 2031, a una CAGR del 10,7% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado      

Market Definition

Laboratory-developed tests (LDTs), also known as in-house developed tests or homebrew tests, are diagnostic tests developed and performed by individual laboratories for specific clinical purposes. These tests are typically designed to detect and measure the presence of a particular biomarker, gene mutation, or other molecular or cellular characteristic associated with a disease or condition. Unlike commercially available tests, which are manufactured and marketed by diagnostic companies, LDTs are developed, validated, and performed within a single laboratory.

Global Laboratory-Developed Tests (LDTs) Market Dynamics

Drivers

• Advancements in Molecular Diagnostics

Molecular techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and gene expression profiling have revolutionized diagnostic testing, allowing more accurate and precise detection of diseases and conditions. These advancements have enabled laboratories to develop more sophisticated and targeted LDTs, driving growth in the market.

• Growing Demand for Personalized Medicine

The growing demand for personalized medicine has also contributed to the market's growth. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, including their genetic makeup, lifestyle, and environment. LDTs play a crucial role in personalized medicine by providing diagnostic information that helps healthcare providers customize patient treatment plans. As personalized medicine becomes more mainstream, the demand for LDTs will continue to rise.

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes has led to a growing need for more accurate and reliable diagnostic tests. LDTs can play a key role in the early detection and monitoring of chronic diseases, helping to improve patient outcomes and reduce healthcare costs. The rising burden of chronic diseases worldwide is driving the demand for LDTs and fueling growth in the market.

Opportunities

• Increasing Focus on Early Disease Detection

Early disease detection is a growing focus as a key strategy for improving patient outcomes and reducing healthcare costs. Early detection allows for timely intervention and treatment, which can significantly improve the chances of successful outcomes. LDTs are well-suited for early disease detection, as they can be developed and validated quickly to target specific biomarkers or disease indicators. The increasing emphasis on early detection is driving the demand for LDTs and creating new opportunities for market growth.

• Increasing Adoption of Point-of-Care Testing

The increasing adoption of point-of-care testing (POCT) is creating new opportunities for the market. POCT allows for rapid diagnostic testing at or near the site of patient care, enabling healthcare providers to make immediate treatment decisions. LDTs are well-suited for POCT, as they can be developed and validated quickly for use in decentralized settings. The growing demand for POCT is driving the need for new LDTs that can be used in these settings, creating new opportunities for market growth.

Restraints/Challenges

• Fluctuating and Intricate Regulatory Environment

One of the significant challenges facing the market is the complex and evolving regulatory landscape. Different countries have varying regulations regarding LDTs, with some jurisdictions imposing strict restrictions or requiring extensive validation and oversight. These regulatory challenges can hinder the market's growth by increasing the cost and time required to develop and launch new LDTs, and creating uncertainty for laboratories and healthcare providers.

• Quality Control and Standardization

Ensuring the quality and consistency of LDTs can be challenging, particularly for laboratories that may not have access to standardized reagents and protocols. Variability in testing methodologies and results can lead to discrepancies in patient care and may undermine the credibility of LDTs. Establishing quality control measures and standardization protocols for LDTs is essential but can be resource-intensive and time-consuming, posing a challenge to market growth.

• Competition from Commercially Available Tests

The availability of commercially available tests for many diseases and conditions can challenge the global LDTs market. Commercial tests often undergo rigorous validation and regulatory approval processes, giving them a perceived advantage regarding reliability and credibility. Laboratories developing LDTs may struggle to compete with these commercially available tests, particularly in gaining acceptance from healthcare providers and payers.

This laboratory-developed tests (LDTs) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the laboratory-developed tests (LDTs) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Guardant Health disclosed that United Healthcare would cover its Guardant360 CDx blood test as a companion diagnostic for advanced lung and breast cancer. This development facilitated the company's expansion of its global footprint
• In May 2022, OPKO Health, Inc. purchased ModeX Therapeutics, a privately held biotechnology firm concentrating on creating innovative multi-specific immune therapies for cancer and infectious diseases. This acquisition aided the company in establishing its global network

Global Laboratory-Developed Tests (LDTs) Market Scope

The laboratory-developed tests (LDTs) market is segmented into eight notable segments based on test type, product type, sample type, therapeutic area, gender, age group, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Test Type

• Clinical Chemistry and Immunology
• Critical Care
• Hematology
• Molecular Diagnostics
• Microbiology
• Other Test

Product Type

• Consumables
• Analyzers and Instruments
• Accessories

Sample Type

• Blood
• Urine
• Tissue
• Cerebrospinal fluid (CSF)
• Others

Therapeutic Area

• Infections
• Genetic Disorders
• Oncology/Cancer
• Autoimmune Disease
• Urology
• Gynecology
• Others

Gender

• Male
• Female

Age Group

• Geriatrics
• Adults
• Pediatric

End User

• Hospital-Based Labs
• Stand-Alone Labs
• Diagnostic Chains
• Academic Institutes
• Clinical Research Organizations
• Specialty Diagnostic Centers
• Others

Distribution Channel

• Direct Tender
• Retail Slaes
• Third Party Distribution
• Others

Global Laboratory-Developed Tests (LDTs) Market Regional Analysis/Insights

The laboratory-developed tests (LDTs) market is analyzed and market size insights and trends are provided by country, test type, product type, sample type, therapeutic area, gender, age group, end user, and distribution channel as referenced above.

The countries covered in the the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market and be the fastest growing region due to the rise in healthcare spending, the increasing incidence of chronic diseases, the expanding elderly population, and growing government funding.

Top of Form

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The laboratory-developed tests (LDTs) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for laboratory-developed tests (LDTs) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the laboratory-developed tests (LDTs) market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Laboratory-Developed Tests (LDTs) Market Share Analysis

The laboratory-developed tests (LDTs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to laboratory-developed tests (LDTs) market.

Some of the major players operating in the laboratory-developed tests (LDTs) market are:

• Roche,(Switzerland)
• bioMérieux,(France)
• Sysmex Corporation (Japan)
• Biomerica, Inc.,(U.S.)
• Bio, Rad Laboratories, Inc.,(U.S.)
• BD (Becton, Dickinson and Company), (Estados Unidos)
• Quest Diagnostics Incorporated, (Estados Unidos) 
• Hologic, Inc., (Estados Unidos)
• Siemens Medical Solutions USA, Inc., (Estados Unidos)
• Abbott, (Estados Unidos)
• Eurofins Scientific, (Estados Unidos)
• Beckman Coulter, Inc., (Estados Unidos)
• 23andMe, Inc., (Estados Unidos)
• OPKO Health, Inc., (Estados Unidos)

SKU-54116